D.C. Law 23-217. Opioid Labeling Amendment Act of 2020.

D.C. Law 23-217. Opioid Labeling Amendment Act of 2020.

AN ACT

To amend section 47-2885.14 of the District of Columbia Official Code to require prescription opioid medications to include a statement that the drug is an opioid and that with opioids there is a risk of overdose and addiction.

BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Opioid Labeling Amendment Act of 2020".

Amend § 47-2885.14

Sec. 2. Section 47-2885.14 of the District of Columbia Official Code is amended as follows:

(a) Designate the existing text as subsection (a).

(b) A new subsection (b) is added to read as follows:

"(b) If the drug contains, or is derived from opium, a label shall be affixed to the container in which such opioid medication is sold or dispensed stating that the drug is an opioid and that with opioids there is a risk of overdose and addiction.".

Sec. 3. Fiscal impact statement.

The council adopts the fiscal impact statement in the committee report as the fiscal impact a statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16,2006 (120 Stat. 2038; D.C. official Code Section 1-201.47.

Sec. 4. Effective date.

This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December

24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.